As of February 9, 2026, Neuronetics Inc has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $1.56, this represents a potential upside of -779.8%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -716.2% |
| Potential Upside (10-year) | -779.8% |
| Discount Rate (WACC) | 5.8% - 8.8% |
Revenue is projected to grow from $75 million in 12-2024 to $159 million by 12-2034, representing a compound annual growth rate of approximately 7.8%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2024 | 75 | 5% |
| 12-2025 | 83 | 11% |
| 12-2026 | 91 | 9% |
| 12-2027 | 98 | 7% |
| 12-2028 | 104 | 7% |
| 12-2029 | 110 | 5% |
| 12-2030 | 119 | 8% |
| 12-2031 | 128 | 8% |
| 12-2032 | 136 | 6% |
| 12-2033 | 147 | 8% |
| 12-2034 | 159 | 8% |
Net profit margin is expected to improve from -58% in 12-2024 to -37% by 12-2034, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2024 | (44) | -58% |
| 12-2025 | (35) | -42% |
| 12-2026 | (37) | -41% |
| 12-2027 | (39) | -40% |
| 12-2028 | (40) | -39% |
| 12-2029 | (42) | -38% |
| 12-2030 | (45) | -38% |
| 12-2031 | (48) | -38% |
| 12-2032 | (51) | -38% |
| 12-2033 | (55) | -37% |
| 12-2034 | (59) | -37% |
with a 5-year average of $2 million. Projected CapEx is expected to maintain at approximately 3% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2025 | 2 |
| 12-2026 | 3 |
| 12-2027 | 3 |
| 12-2028 | 3 |
| 12-2029 | 3 |
| 12-2030 | 3 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 90 |
| Days Inventory | 145 |
| Days Payables | 113 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 3M/2025 | (9) | (3) | 1 | 1 | (8) |
| 2026 | (40) | (14) | 3 | 1 | (30) |
| 2027 | (42) | (14) | 3 | 1 | (32) |
| 2028 | (43) | (15) | 3 | 2 | (34) |
| 2029 | (44) | (15) | 4 | 1 | (33) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -716.2% |
| 10-Year DCF (Growth) | 0.00 | -779.8% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Neuronetics Inc (STIM) a buy or a sell? Neuronetics Inc is definitely a sell. Based on our DCF analysis, Neuronetics Inc (STIM) appears to be overvalued with upside potential of -779.8%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $1.56.